Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

756 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group.
Kasai S, Itonaga H, Niino D, Miyoshi H, Kato T, Imanishi D, Fujioka M, Furumoto T, Sato S, Sawayama Y, Taguchi J, Imaizumi Y, Hata T, Yoshida S, Moriuchi Y, Ohshima K, Miyazaki Y. Kasai S, et al. Int J Hematol. 2020 Oct;112(4):524-534. doi: 10.1007/s12185-020-02926-6. Epub 2020 Jun 25. Int J Hematol. 2020. PMID: 32588395
Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia.
Fujioka M, Itonaga H, Kato T, Nannya Y, Hashimoto M, Kasai S, Toriyama E, Kamijo R, Taguchi M, Taniguchi H, Sato S, Atogami S, Imaizumi Y, Hata T, Moriuchi Y, Ogawa S, Miyazaki Y. Fujioka M, et al. Among authors: kasai s. Int J Hematol. 2020 Feb;111(2):311-316. doi: 10.1007/s12185-019-02731-w. Epub 2019 Sep 12. Int J Hematol. 2020. PMID: 31515708
Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
Sakamoto H, Itonaga H, Sawayama Y, Furumoto T, Fujioka M, Chiwata M, Toriyama E, Kasai S, Nakashima J, Horai M, Kato T, Sato S, Ando K, Taguchi J, Imaizumi Y, Yoshida S, Hata T, Moriuchi Y, Miyazaki Y. Sakamoto H, et al. Among authors: kasai s. Hematol Oncol. 2020 Apr;38(2):162-170. doi: 10.1002/hon.2712. Epub 2020 Jan 26. Hematol Oncol. 2020. PMID: 31922287
Correction to: Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group.
Kasai S, Itonaga H, Niino D, Miyoshi H, Kato T, Imanishi D, Fujioka M, Furumoto T, Sato S, Sawayama Y, Taguchi J, Imaizumi Y, Hata T, Yoshida S, Moriuchi Y, Ohshima K, Miyazaki Y. Kasai S, et al. Int J Hematol. 2020 Dec;112(6):906. doi: 10.1007/s12185-020-03019-0. Int J Hematol. 2020. PMID: 33085031
The response-guided ATG treatment provides a survival benefit and KPS recovery for patients with steroid refractory acute GVHD: The Nagasaki Transplant Group Experience.
Fujioka M, Itonaga H, Furumoto T, Kasai S, Sakamoto H, Kitanosono H, Kato T, Horai M, Sato S, Sawayama Y, Taguchi J, Imaizumi Y, Hata T, Yoshida S, Moriuchi Y, Miyazaki Y. Fujioka M, et al. Among authors: kasai s. Transpl Immunol. 2021 Aug;67:101417. doi: 10.1016/j.trim.2021.101417. Epub 2021 May 28. Transpl Immunol. 2021. PMID: 34058354
Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
Chiwata M, Itonaga H, Sato S, Hashimoto M, Fujioka M, Kasai S, Sakamoto H, Toriyama E, Nakashima J, Kamijo R, Kitanosono H, Kobayashi Y, Horai M, Taguchi M, Matsuo M, Makiyama J, Takasaki Y, Matsuo E, Horio K, Ando K, Sawayama Y, Taguchi J, Kawaguchi Y, Tsushima H, Imanishi D, Imaizumi Y, Yoshida S, Jo T, Nonaka H, Moriuchi Y, Nagai K, Yokota KI, Hata T, Miyazaki Y. Chiwata M, et al. Among authors: kasai s. Intern Med. 2021 Jul 15;60(14):2207-2216. doi: 10.2169/internalmedicine.6620-20. Epub 2021 Feb 22. Intern Med. 2021. PMID: 33612681 Free PMC article.
Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome.
Hashimoto M, Itonaga H, Nannya Y, Taniguchi H, Fukuda Y, Furumoto T, Fujioka M, Kasai S, Taguchi M, Taniguchi H, Sato S, Sawayama Y, Atogami S, Iwasaki K, Hata T, Soda H, Moriuchi Y, Nakata K, Ogawa S, Miyazaki Y. Hashimoto M, et al. Among authors: kasai s. Intern Med. 2020 Apr 15;59(8):1081-1086. doi: 10.2169/internalmedicine.3770-19. Epub 2019 Dec 26. Intern Med. 2020. PMID: 31875636 Free PMC article.
Selenoprotein-Mediated Redox Regulation Shapes the Cell Fate of HSCs and Mature Lineages.
Aoyama Y, Yamazaki H, Nishimua K, Nomura M, Shigehiro T, Suzuki T, Zang W, Tatara Y, Ito H, Hayashi Y, Koike Y, Fukumoto M, Tanaka A, Zhang Y, Saika W, Hasegawa C, Kasai S, Kong Y, Minakuchi Y, Itoh K Professor, Yamamoto M, Toyokuni S, Toyoda A, Ikawa T, Takaori-Kondo A, Inoue D. Aoyama Y, et al. Among authors: kasai s. Blood. 2025 Jan 7:blood.2024025402. doi: 10.1182/blood.2024025402. Online ahead of print. Blood. 2025. PMID: 39775457
756 results